Drug Immunoconjugates for Vaccine Development
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 20 May 2025 | Viewed by 7
Special Issue Editors
Interests: drug immunoconjugates; vaccine; synthetic organic and medicinal chemistry
Interests: cancer therapy; drug delivery; drug targeting; infectious disease; micelle; nanoparticles; nanotechnology; polymers; targeted therapies; HIV; antibody engineering; antibody–drug conjugates
Special Issues, Collections and Topics in MDPI journals
Interests: neuroscience; behavioral pharmacology; medication development; vaccines; immunology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The development of potent vaccines remains a top priority in biomedical research, especially for addressing emerging infectious diseases, cancer, opioid addiction, and other critical health challenges. Drug immunoconjugates, which merge immunogenic molecules with therapeutic agents, represent a promising strategy for enhancing vaccine efficacy by directing immune activation toward specific antigens and stimulating targeted immune responses. These conjugates offer unique advantages by targeting specific immune cells, enhancing antigen presentation, and enabling the controlled release of adjuvants, together inducing robust and durable immunity.
This Special Issue compiles research on the latest breakthroughs, challenges, and innovations in the field of drug immunoconjugates for vaccine development. By focusing on design principles, mechanisms of action, targeting strategies, and both preclinical and clinical evaluations, we will present comprehensive insights into the potential of drug immunoconjugates to address limitations in traditional vaccines, particularly for rapidly mutating pathogens and tumor antigens. We invite contributions across diverse topics, including conjugate synthesis, immune cell activation mechanisms, and clinical progress, all with an emphasis on advancing targeted and long-lasting immune responses.
This Special Issue underscores the critical role of drug immunoconjugates in next-generation vaccine platforms, offering a path to safer, more effective immunotherapies.
Dr. Anantha Lakshmi Duddupudi
Dr. Murali Mohan Yallapu
Dr. Colin N. Haile
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine development
- immunogenic carriers
- targeted immune responses
- antigen presentation
- immune cell targeting
- controlled release adjuvants
- cancer immunotherapy
- infectious disease vaccines
- opioid addictions
- prophylactic vaccines
- therapeutic vaccines
- conjugate design and synthesis
- mechanisms of action
- preclinical evaluation
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
